Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
IgM and IgG antibodies to human T cell lymphotropic retrovirus (HTLV-III) in lymphadenopathy syndrome and subjects at risk for AIDS in Italy.
Br Med J (Clin Res Ed). 1985 Jul 20;291(6489):165-6. Unique Identifier : AIDSLINE MED/85253765 Aiuti F; Rossi P; Sirianni MC; Carbonari M; Popovic M; Sarngadharan MG; Contu L; Moroni M; Romagnani S; Gallo RC
Abstract:
A study was performed to assess the prevalence of specific antibodies to human T cell lymphotropic retrovirus (HTLV-III) in patients with lymphadenopathy syndrome, patients with the acquired immune deficiency syndrome (AIDS), and those at risk of AIDS. Serum samples were obtained from these groups and from healthy controls in selected cities in Italy, and antibodies to HTLV-III were measured by immunofluorescence assay and, in a few patients, by Western blotting. In addition, IgM antibody values were measured in 82 of those positive for HTLV-III. Altogether, 235 out of 320 patients with lymphadenopathy syndrome had antibodies to HTLV-III, the proportions being highest in haemophiliacs, homosexuals, and drug addicts from Rome; 11 out of 12 patients with AIDS had antibodies; 78 out of 439 subjects at risk for AIDS had antibodies; and six out of 30 patients with lymphadenopathy syndrome and positive for HTLV-III antibodies and nine of 52 patients at risk of AIDS had a detectable titre of IgM. HTLV-III is widespread in groups at risk of AIDS in Italy, and antibodies to HTLV-III are highly prevalent in patients with lymphadenopathy syndrome. A higher proportion of drug abusers were positive for antibodies than in previous studies. HTLV-III infection would appear to be spread mainly in compromised hosts, as none of the controls were positive for antibodies.
Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Adolescence Adult Aged Antibodies, Viral/*ANALYSIS Female Hemophilia/IMMUNOLOGY Homosexuality Human HTLV-BLV Viruses/*IMMUNOLOGY IgG/*IMMUNOLOGY IgM/*IMMUNOLOGY Immunoblastic Lymphadenopathy/*IMMUNOLOGY Italy Male Middle Age Risk Substance Dependence Support, Non-U.S. Gov't JOURNAL ARTICLE
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
